Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

T1810000

Tranexamic acid

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

trans-4-(Aminomethyl)cyclohexanecarboxylic acid, AMCA, AMCHA, HAKU, TAMCHA, Tranexamic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
H2NCH2C6H10CO2H
Numéro CAS:
1197-18-8
Poids moléculaire :
157.21
Numéro Beilstein :
2207452
Numéro MDL:
MFCD00001466
Code UNSPSC :
41116107
ID de substance PubChem :
329826687
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

tranexamic acid

Fabricant/nom de marque

EDQM

Pf

>300 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

Clé InChI

GYDJEQRTZSCIOI-LJGSYFOKSA-N

Informations sur le gène

human ... PLG(5340)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Tranexamic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H315,H319,H335

Classification des risques

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1961-1968 (2013-11-08)
Approximately one-third of patients undergoing total knee replacement require one to three units of blood postoperatively. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that has been successfully used intravenously to stop bleeding after total knee replacement. A topical application
V Sharma et al.
Anaesthesia, 69(2), 124-130 (2014-03-04)
Because of a lack of contemporary data regarding seizures after cardiac surgery, we undertook a retrospective analysis of prospectively collected data from 11 529 patients in whom cardiopulmonary bypass was used from January 2004 to December 2010. A convulsive seizure
S Grassin-Delyle et al.
British journal of anaesthesia, 111(6), 916-924 (2013-07-25)
Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either
Sattar Alshryda et al.
The Journal of bone and joint surgery. American volume, 95(21), 1969-1974 (2013-11-08)
Approximately one-third of patients undergoing total hip replacement surgery require one to three units of blood postoperatively. Tranexamic acid is a synthetic antifibrinolytic agent that has been successfully used intravenously to control bleeding after total hip replacement. A topical application
Kristen A Matteson et al.
Obstetrics and gynecology, 121(3), 632-643 (2013-05-03)
To compare the effectiveness of nonsurgical abnormal uterine bleeding treatments for bleeding control, quality of life (QOL), pain, sexual health, patient satisfaction, additional treatments needed, and adverse events. MEDLINE, Cochrane databases, and Clinicaltrials.gov were searched from inception to May 2012.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique